Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-
developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with …

The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs)
gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers …

Background We aimed to compare overall survival after standard-dose versus high-dose
conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to …

Protein–protein interactions (PPIs) are involved at all levels of cellular organization, thus
making the development of PPI inhibitors extremely valuable. The identification of selective …

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in
homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies. With …

The human epidermal growth factor receptor (EGFR) family consists of four members that
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …

ConsensusPathDB consists of a comprehensive collection of human (as well as mouse and
yeast) molecular interaction data integrated from 32 different public repositories and a web …

Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …